A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery

Lee, Tong-Young; Wu, Han-Chung; Tseng, Yun-Long; Lin, Chin‐Tarng

doi:10.1158/0008-5472.can-04-1948

Cited by 78 publications

(74 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Procedures for the preparation of peptide-liposomes containing doxorubicin were adapted from the methods published in previous reports (33,36). Briefly, peptide ligands were coupled to NHS/PEG/DSPE [N-hydroxysuccinimidocarboxyl/polyethylene glycol (PEG; average molecular weight, 3,000)-derived/distearoylphosphatidylethanolamine; NOF Corporation] in a 1:1.5 molar ratio.…”

Section: Methodsmentioning

confidence: 99%

“…Peptidyl-PEG/DSPE was transferred to preformed liposomes after coincubation at a temperature above the transition temperature of the lipid bilayer (38). The liposomes had a particle size ranging from 65 to 75 nm in diameter (33). There were 300 to 500 peptide molecules per liposome, computed as described previously (39).…”

Section: Methodsmentioning

confidence: 99%

“…They can be used to search for disease-specific antigen mimics (29)(30)(31), and to determine cellspecific (32,33) and organ-specific peptides (5,28,34). Screening phage-displayed peptide libraries against specific target tissues is therefore a direct and fast method for identifying peptide sequences which might be used for the targeting of drug or gene delivery vectors.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery

et al. 2007

Self Cite

View full text Add to dashboard Cite

Antiangiogenesis therapies for the treatment of cancers hold the promise of high efficacy and low toxicity. In vivo phage display was used to identify peptides specifically targeting tumor blood vessels. The peptide SP5-52 recognized tumor neovasculature but not normal blood vessels in severe combined immunodeficiency mice bearing human tumors. Synthetic peptide was shown to inhibit the binding of PC5-52 phage particles to the tumor mass in the competitive inhibition assay. Several selected phage clones displayed the consensus motif, proline-serine-proline, and this motif was crucial for peptide binding to the tumor neovasculature. SP5-52 peptides also bound vascular endothelial growth factorstimulated human umbilical vein endothelial cells and blood vessels of human lung cancer surgical specimens. Furthermore, this targeting phage was shown to home to tumor tissues from eight different types of human tumor xenografts following in vivo phage display experiments. An SP5-52 peptide-linked liposome carrying doxorubicin enhanced the therapeutic efficacy of the drug, markedly decreased tumor blood vessels, and resulted in higher survival rates of human lung and oral cancer-bearing xenograft mice. The current study indicates that ligand-targeted therapy offers improved therapeutic effects over conventional anticancer drug therapy, and that the peptide SP5-52 specifically targets tumor neovasculature and is a good candidate for targeted drug delivery to solid tumors. [Cancer Res 2007;67(22):10958-65]

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…[18][19][20] The modification of nanoparticles with peptide ligands enables their specific accumulation in target organs and tumor cells by receptormediated uptake such as endocytosis. 21,22) In addition, the physicochemical properties of their surface such as hydrophobicity and hydrophilicity also affect the biodistribution of nanoparticles. Nanoparticles with hydrophobic surfaces interact with blood components and are subsequently cleared by the reticuloendothelial system (RES).…”

Section: Introductionmentioning

confidence: 99%

Peptide-Based Cancer-Targeted DDS and Molecular Imaging

2017

View full text Add to dashboard Cite

Targeting cancer cell-surface receptors is an attractive approach for cancer treatment and diagnosis. Peptides having high binding affinities to receptors overexpressed in cancer cells are useful because of their simple structure, low immunogenicity, and easy, cost-effective chemical synthesis. A number of peptide ligands have been developed for cancer cell-surface receptors and applied to nanoparticles with anticancer drugs, genes, small interfering RNAs (siRNAs), and molecular imaging agents. In particular, recent findings have revealed that peptide-modified PEGylated liposome-encapsulated drugs are effective in cancer-targeted therapy and cancer cell-specific imaging. This review discusses peptide-modified nanoparticles for drug delivery systems (DDS) and molecular imaging, focusing on peptide ligands for somatostatin receptors, integrin, transferrin receptor, human epidermal growth factor 2 (HER2), etc. In addition, methods to improve binding affinity or endosomal escape with spacer peptides and stimuli (internal and external) are discussed.

show abstract

“…The biopanning technique has been shown to be a powerful tool for identifying specific ligands on target organs and tumors, as it enables forced evolution of very high-affinity targeting peptides through rounds of selection of living libraries of peptides presented on the surface of the bacteriophage particle (9)(10)(11)(12). This technique has classically been used to iteratively produce peptides binding purified cell surface markers (13,14), cultured cell lines (15,16), or tumor-bearing animals (17)(18)(19). We utilized a peptide-presenting bacteriophage library on the basis of a combinatorial library of random peptide 12mers fused to a minor coat protein pIII of the M13 bacteriophage containing approximately 2.7 Â 10 9 different sequences, and different peptides selective for the target cells were identified with successive rounds of biopanning.…”

Section: Introductionmentioning

confidence: 99%

COP35, a Cholangiocarcinoma-Binding Oligopeptide, Interacts with the Clathrin Heavy Chain Accompanied by GRP78

Kitahara

Masumoto

Parker

et al. 2011

Molecular Cancer Research

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a common carcinoma of the liver, and the majority of patients with CCA have a poor prognosis due to the lack of effective nonsurgical therapies in addition to its rapid progression and inoperability at the time of diagnosis. The development of novel nonsurgical therapeutics that efficiently target CCA could significantly improve the prognosis for patients presenting with CCA. Here, we describe the iterative production and characterization of a novel peptide, designated COP35 (CCA-binding oligopeptide 35), which binds selectively to human CCA, identified by bacteriophage biopanning using the intrahepatic CCA cell line RBE and the normal cholangiocyte cell line MMNK-1. COP35 was found to augment the growth inhibitory effects of 5-fluorouracil (5-FU) against RBE cells. Utilizing pull-down assay and liquid chromatography, we identify the clathrin heavy chain accompanied by GRP78/BiP as a COP35-binding partner. In summary, we identify COP35 as a possible candidate for peptide-targeted therapies for CCA. Mol Cancer Res; 9(6); 688-701. Ó2011 AACR.

show abstract

A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery

Abstract: ABSTRACT

Cited by 78 publications

References 30 publications

Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery

Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery

Peptide-Based Cancer-Targeted DDS and Molecular Imaging

COP35, a Cholangiocarcinoma-Binding Oligopeptide, Interacts with the Clathrin Heavy Chain Accompanied by GRP78

Contact Info

Product

Resources

About